Mitsubishi UFJ Asset Management UK Ltd. Has $467,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Mitsubishi UFJ Asset Management UK Ltd. boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 500.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 6,000 shares of the medical device company’s stock after buying an additional 5,000 shares during the period. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in DexCom were worth $467,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of DXCM. Versant Capital Management Inc bought a new position in DexCom during the fourth quarter worth about $25,000. Riverview Trust Co increased its position in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. RPg Family Wealth Advisory LLC acquired a new position in DexCom during the third quarter valued at approximately $57,000. Covestor Ltd boosted its stake in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its position in DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DXCM. Canaccord Genuity Group raised their target price on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Sanford C. Bernstein boosted their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Royal Bank of Canada decreased their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.29.

DexCom Stock Up 2.3 %

DexCom stock opened at $86.32 on Wednesday. The stock has a market capitalization of $33.72 billion, a price-to-earnings ratio of 51.69, a PEG ratio of 2.21 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The business has a fifty day moving average price of $78.46 and a 200-day moving average price of $77.56.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.